© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Ladies and gentlemen, good day, and welcome to Persistent Systems Earnings Conference Call for the Fourth Quarter of FY '24 ended March 31, 2024. We have with us on the call today: Dr. Anand Deshpande, Chairman and Managing Director; Mr. Sandeep Kalra, Executive Director and Chief Executive Officer; Mr. Sunil Sapre, Executive Director and Chief Financial Officer; and Mr. Saurabh Dwivedi, Head of Investor Relations. [Operator Instructions] Please note, this conference is being recorded. I now hand the conference over to Mr. Sandeep Kalra. Thank you, and over to you, sir.
Thank you, moderator. Good morning and good evening to all of you, depending on where you are joining us from. I'm pleased to share that we concluded our Board meeting today at our Bridgewater office in New Jersey, U.S. I'm joined today by our leadership team here for this call. I would like to start by wishing a happy New Year to all of you who are celebrating the start of a new year as per the Indian calendar. With this, let me start with a quick financial summary. We delivered revenues of USD 310.9 million for Q4 FY '24. This translates to a growth of 3.4% quarter-on-quarter and 13.2% on year-on-year basis. In up terms, the growth for the quarter came in at 3.7% quarter-on-quarter and 14.9% on a year-on-year basis. This is our first ever quarter wherein we crossed the quarterly getting run rate of INR 2,500 crores, which translates into an annual run rate in excess of INR 10,000 crores. On a constant currency basis, the growth for the quarter came in at 3.4%, same as the dollar revenue growth. For the full year FY '24, we achieved a revenue of USD 1,186 million, giving us a growth of 14.5% on a year-on-year basis compared to financial year '23. I would like to emphasize that this is purely an organic growth, which basically means that we did not have any acquisitions through the financial. Coming to the EBIT side. Our EBIT margin for the Q4 came in at 14.5%. The Q4 EBIT margin was in a narrow band compared to the last quarter. This was on account of ramp-up of larger vendor consolidation deals that we won over the last couple of quarters with a relatively higher on-site proportion to stack. The ramp-up in this quarter included a onetime transition cost, along with lower utilization and higher travel costs. This impacted the EBIT, which was compensated by a reduction in earnout liability with respect to one of our acquisitions that did not perform in line with our business case. So we will provide more color on the EBIT margin movement later in this call. During the next 12 months, given the challenging macro environment, our goal is to maintain top quartile growth while maintaining margins at the current level. We'll be working towards improving utilization, on-site offshore mix and other operational efficiencies to ensure we keep moving towards our medium-term target of improving margins by 200 to 300 basis points over the next 3 years. Now coming to the order book for the quarter. The total contract value for the quarter came in at USD 447.7 million with TCV of new bookings being $302 million. The annual contract component of this TCV is $36.8 million, of which ACV from new bookings contributed to $284.5 million. As most of you are aware, we typically see higher quantum of renewals and hence, overall bookings in the October, November, December quarter, which corresponds to end of financial year for our North American customers. The sequential decline of bookings in this quarter is a reflection of the seasonality that we have observed for the last several years. Also, please note that as always, these TCV and ACV numbers include all bookings, small and large renewals as well as new bookings across existing and new customers. Coming to the client engagement side. Let me give you some color on our client engagements by buckets. Our top 1 customer declined by $3.2 million quarter-on-quarter. This was in line with the planned partial ramp down of a large 5-year deal that we had announced in financial year '22. We will test healthy growth among various client buckets with our top 5 customer revenue up 7.9% quarter-on-quarter; top 10 up 5.4% quarter-on-quarter; top 20 up 2.9% quarter-on-quarter basis. Our top 50 customer portfolio delivered a robust growth of 4.3% in Q4, which is better than the overall revenue growth of the company in this quarter. In Q4, we reported a total of 178 customers with trailing 12-month revenue in excess of USD 1 million. I'm happy to report the entry of new customers in the dollar $30 million plus, $10 million to $20 million and $5 million to $10 million buckets. All of these have potential to scale up further in the future quarters. From a client concentration perspective, the contribution from top 10 customers reached 40% in this quarter for the first time since Q1 financial year. This is partly on account of the growth in a couple of large customer relationships across healthcare verticals and BFSI industry verticals. This is a demonstration of our ability to scale customer relationships significantly and oftentimes in competition with larger IT services players. Coming to the geographical data. From a geography perspective, for the full financial year '24, North America revenue grew by a healthy 16.8% year-on-year in U.S. dollar terms ahead of the company average; Europe grew 13.4% year-on-year; rest of the world grew 4.3% year-on-year; while India grew by 0.6% year-on-year. Coming to the people front. At the end of Q4, our total headcount stood at 23,850, a net increase of 514 from Q3. Most of the headcount increase in this quarter came from lateral hires. On-site hiring was linked to revenue ramp up while offshore hiring is towards revenue ramp-up as well as build up for capacity for future ramp ups. With this, the blended utilization for the quarter came in at 80% against 81.5% in Q3. The trailing 12-month attrition for the quarter came in at 11.5% compared to 11.9% in Q3. Attrition has come down to a comfortable band over the last few quarters in line with the industry. Moving on from operational metrics to certain strategic highlights for the quarter. First, on generative AI. In Q3, financial year '24, we had provided you with a comprehensive update regarding our pivotal shift towards AI-powered beginning and enterprise monetization initiatives. As you may recall, Persistent has a long history with AI. While our experience goes beyond the current buzz around generative AI, FY '24 has had lay a strong foundation in our journey, fueling our acceleration in the space. I'm happy to report we continue to deliver transformative solutions for our customers, Liberty, Generative AI and AI at broad. Over the course of the last quarter, multiple proof of concepts have been progressing towards scale production levels. AI is opening up significant opportunities for asset persistent in 2 broad engines, AI for product engineering and AI for the enterprises. We will provide you some more details on our solution-centric approach in each of these opportunity themes. On the engineering front, we are focusing on delivering value to our customers through productivity gains using AI and automation tools across the product development life side. Over the last 30-plus years, we have been leaders in product engineering, be it scale engineering, modernization or sustaining inline. As you may be aware, most enterprise software is complex as over 60% to 70% of the code in any enterprise software comprises of third-party open source components, customized kernels and most importantly, called with interdependent repositories. Recent engineering solutions such as copilots and core tools powered by large language models have succeeded in offering high-quality solutions to localized coding problems. However, the repository level coding is primarily a planning problem and cannot be solved directly using these code assistants. That's where Sasa, our digital engineering powered enterprise BI platform comes in. This is a platform that's based on a novel combination of an incremental dependency, change impact analysis and an adaptive planning algorithm and much more. It addresses the depository level coding and planning. The platform harnesses the power of hybrid language models, including fine-tuned small language models, machine learning and a vast multidimensional notes. Sapa delivers significant efficiencies, quality enhancements, improved security posture and cost savings throughout the product development life cycle. The key highlights for Saswa include: team-based releases, which include end-to-end planning and execution of software updates such as porting and modernization; multidimensional knowledge base for insights on complex code to the net level of interdependencies; digital win reflecting key resource capabilities, enabling use cases such as derisked knowledge transition; the challenge of higher costs related with GenAI has been addressed by Sasa using fine-tuned small language models that provide LLM great results while being hosted on a relatively lower cost infrastructure. As you are aware, we own a number of software products as a part of our Accelerite business. SAS has been tested extensively with most of these products, yielding significant productivity gains over time and is a showcase for us and our customers' prospects alike. Coming to the enterprise side. On the enterprise side to accelerate GenAI powered enterprise transformation, we continue to invest and strengthen our GenAI hub so that our customers can create faster, more efficient and secure GenAI experiences at scale anchored by the basic principles of responsibility. Enterprises can adopt GenAI across large language models and clou with no provider lock-in integrated with existing assets and enabled by prewi accelerators using that GenAI. Let me talk about the select deal wins in the generate. First, on the engineering side. For a leading enterprise software company, we have won an outcome linked deal, encompassing sustaining engineering and future enhancements while one of their key software products, leveraging us as to our platform. The organization wanted to address some of the challenges around slow product releases due to legacy technologies, high technical debt encompassing issues related to code quality, security and user experience. The code repository for this product line has over 15 million lines of code and a number of third-party open source software companies. These technical challenges were negatively impacting their business. Leveraging SFS and fine-tuned SLM, we would be responsible for substantial reductions in technical debt and the outcome metrics for us include shorter release cycles as well as overall lower cost of sustaining engineering coupled with revenue acceleration met. On the enterprise side, we won a 3-year deal to develop and design GenAI-based state through processing platform for a listed insurance distribution cooperation in the U.S. This firm specializes in advisory, underwriting and customized insurance solutions. Under this deal, we will be responsible for delivering enhanced end user customer experiences as well as optimize Tier 2 processing of code, buying and issue process, along with the operations of the same. The platform will support end-to-end processing of a variety of documents such as carrier downloads, policy contracts, employee records and other policy administration documents. The core stack will be leveraging Azure OpenAI, PZ vector and multiple API gateways. This platform aims to deliver rapid expansion of the cooperation across multiple lines of businesses spanning 50-plus states in events. Connect win is with a large energetical instruments and Specialty Diagnostics Cooperation. Here, we are working collaboratively with them in building a GenAI-based recommendation engine. The engine will enable mapping of customer queries with a product catalog for effective cross-sell and upsell. The solution leverages Azure OpenAI, GPT4 as the conjection model and Lantana the. The expected benefits from the solution include significant incremental revenue for the customer over a period of time as the solution gets deployed as well as a strong reduction in the number of FTEs required to perform these tasks over time. In addition to the above examples, there are multiple use cases of generative AI being implemented within Persistent as a customer, making our operations more agile and enhancing our employee expense. In summary, we remain steadfast in our approach to making AI and GenAI, the way of working at Persistent and with our customers will provide further progress on this topic in subsequent quarters. Coming to the dividend side. I'm pleased to share with you that the Board of Directors recommended a final dividend of INR 10 per share on the face value of INR 5 per share. This dividend payout will require shareholder approval during the Annual General Meeting as per statutory note. As you may recall, in January 2024, the Board has declared an interim dividend of INR 32 per share on the face value of INR 10 per share. It's our endeavor to maintain a healthy balance in our capital allocation through a consistent dividend payout ratio while augmenting our growth through capability-led acquisitions. Coming to the ESG updates. I'm happy to share that Persistent was named as one of India's leading listed ESG entities for 2024 by tenants. As you may be aware, our aspiration is to achieve carbon neutrality for Scope 1 and Scope 2 emissions and 100% renewable energy sourcing by the middle of FY '25, and I'm happy to say we are well on the way to do this. We are also committed to set near- and long-term company-wide emission reductions in line with science-based Net Zero with the SPT. In summary, we are pleased with our performance in FY '24 in linguiness environment. I would now like to invite Sunil, our CFO, to give more color on quarterly financials in related remarks. After that, Saurabh, our Investor Relations head, will give you more details on key client wins, analyst awards and other requisitions for the quarter. So then over to you, Sunil.
Thank you, Sandeep, and good morning. Good day to all, and thanks a lot for taking the time to join us today. Sandeep has walked us through the market outlook. Let me walk you now through the financial performance for the quarter ending 31 March 2024. The revenue for the quarter at $310.9 million reflected quarter-on-quarter growth of 3.4% and Y-o-Y growth of 13.2%. Revenue for the quarter in INR terms was INR 905 million, which translates into growth of 3.7% quarter-on-quarter and 14.9% Y-o-Y. For the full year, the revenue was $1,186 million, a growth of 14.5%. And in INR terms, the revenue was INR 9.8 million to INR 15.9 million with a growth of 17.6%. Coming to segmental growth for the quarter. Healthcare and Life Sciences improved by 15% quarter-on-quarter, FSI grew by 2%, while high tech and emerging vertical declined by 0.9% on account of planned ramp down in a large multiyear program in the top 1 customer. Excluding this top 1 customer, the High Tech & Emerging Verticals segment grew by 1.6% quarter-on-quarter. EBIT margin for the quarter largely remained flat compared to Q3. And let me now give you a walk-through on the EBIT margin for the quarter. Revenue growth in Q4 has been led by higher on-site ramp-up in some of our large customers. This growth is driven by vendor consolidation, and we have leveraged contractors for this initial ramp-up. You will notice the contractor cost in this quarter has increased to 14.1% of revenues. There was onetime cost of transition related to this ramp-up in multiple deals, which impacted margins by 110 basis points. During this quarter, we also added lateral hires at offshore to build capacity to flow and planned transition from on-site to offshore in certain projects. This impacted utilization and in turn margins by about 50 basis points. Further, the pressures who had joined us in Q2 are now part of the billable pool. So while this doesn't have a cost impact directly, the utilization number gets adjusted because of which overall utilization is reduced from 81.5% to 80% in this quarter. But you will observe that this capacity of lateral hires and pressures will be a margin lever for us in subsequent quarters. There was an elevated travel cost on account of the planning and budgeting exercise for fiscal year '25 that we undertook in Q4, which impacted margins by about 40 basis points. All of these headwinds put together impacted EBIT margins cumulatively by 200 basis points, which was largely compensated by a reduction in earnout liability related to one of our acquisitions, which did not perform as per business plan. Coming to depreciation and amortization, it was almost similar at 3.1% as the previous quarter. EBIT for the full fiscal year '24 was 14.4% compared to 14.9% in FY '23. And you will notice that majority of the EBIT decline is attributable to the investment we have made in building sales and marketing capacity as well as building ExGen technology assets, including in the unit. These investments are critical from the perspective of driving future growth. We are cognizant of the need to drive operational efficiencies to continue our growth journey in the future and march towards the goal of expanding our margins in the medium term. To this end, we have focused initiatives that are being led by our operational leadership. Treasury income for the quarter was INR 26 million as against INR 181.1 million, mainly on account of higher cash balance. OCF to EBITDA for the quarter was 0.76 for the full year, post EBITDA was 0.73. This compares with the last year of EBITDA of 0.60. The free cash flow for the year was INR 732 million as compared to INR 925 million as there were no acquisitions during the year. We had a ForEx loss of INR 15.5 million as against a gain of INR 80.9 million in the previous quarter. Profit before tax for the quarter was INR 3954.9 million at 15.3% as against 15.6% in the previous quarter. ETR for the quarter was 20.3%, mainly due to the tax credit on account of ISA perquisite income reported by our U.S. employees on which the company gets a tax credit. ETR for the year came in at 24.5% and is likely to remain in the same range for the next year. PAT for the quarter was INR 3153.2 million at 12.2%. PAT for the full year was INR 1093.49 million at 11.1%. And this is the first year in which our PAT has crossed the important milestone of INR 1,000 crores. EPS for the fiscal year '24 was INR 144.87 as against INR 123.734 per share. This is on a like-to-like comparison of INR 10 per share. The growth that this implies is 17.1% in EPS. The operational CapEx for the quarter was INR 295.5 million. Total cash and investments on the books are INR 18,585 million as compared to INR 18,472 million at the end of the. DSO came in at 63 days as against 66 days in the previous quarter. Forward contracts outstanding at the end of March was 260 million at an average rate of 34.16 per. As Sandeep mentioned, the Board of Directors has declared a recommended a final dividend of INR 10 on the face value of INR 5 each. It should be paid after the shareholders' approval at the ensuing General Meeting. So on a total dividend payout basis, it translates to 36% dividend payout ratio, which is in line with our bold branded on guidance. In FY '23, the total dividend paid out to the shareholders was INR 50 per share on the face value of INR 10 per share, including special dividend of INR 10 per share and reaching $1 billion milestone. And compared to that INR 50 for the last year. The dividend for this year comes to. Thank you all, and hand it to Saurabh now for covering deal wins and awards at.
Thank you, Sunil. I will now talk about key deal wins for Q4 by industry segments. Let me begin with software, high-tech and emerging industries, our largest vertical. Persistent was selected by one of the largest global technology companies to enable open source software porting and validation for its flagship infrastructure offering, both on-prem and cloud. This is a mission-critical offering to support large volume of data workloads for Fortune 500 companies. The benefit to the customer includes enhanced ecosystem play and accelerated support for various independent software vendors. Persistent was selected by the Energy division of one of the largest European conglomerates to set up an offshore development center to support research and development for its core energy, implementation and control platform. This is the first large win for Persistent in the energy sector in Europe. The benefit to the customer includes improved security posture and modernization of the core platform. Persistent was selected by a leading consumer intelligence company as a strategic partner for its platform engineering and IT transformation initiatives. This includes migration from legacy middleware stack to open source technology as well as engineering, artificial intelligence, machine learning and security platforms. The benefit to the customer includes reduction in cost, especially in the data capture and processing unit. Coming to Banking, Financial Services and Insurance. Persistent was selected by the financial services subsidiary of one of the largest automobile companies globally to drive new CRM experiences, including automation of workflows for customer sales journey, contact center and marketing automation with real-time offers. The benefit to the customer includes improved agent productivity, sales application closure time and revenue gains from real time recommendation. Persistent was selected by a leading fintech organization in the U.K. to build the next-generation banking platform that will be marketed to new banks and building societies in the U.K. and other emerging markets globally. This engagement leverages Persistent's digital banking solution and its digital engineering capabilities in the BFSI domain. The benefit to the customer includes revenue enhancements through new customer acquisitions. Persistent was selected by one of the leading Indian banks to undertake transformation of its loan origination platform across different lines of businesses, including vehicle finance, personal loans, consumer durable loans, housing loans, business loans and Kisan credit schemes. This renewal deal is a significant testament to our capability in the digital transformation landscape in the Indian banking sector. The benefit to the customer includes substantial reduction in launching new products and cross-sell and upsell of lending products. And finally, within our Healthcare and Life Sciences vertical. Persistent was selected by one of the largest biopharmaceutical companies to build and launch a centralized patient relationship management system that enables business capabilities such as patient enrollment and onboarding, access and reimbursement, patient engagement and operational performance reporting. The benefit to the customer includes increase in patients served and reduced turnaround time for benefit verification. Persistent was selected by one of the largest drug wholesale company and a contract research organization as a technology partner to develop a modern data ingestion and analytics platform to support intelligent and efficient data insights requirements of the business. This deal win is unique since it involves close collaboration with one of the largest data warehousing company as well as with a hyperscaler. The benefit to the customer includes improved supply chain effectiveness. Persistent was selected by one of the largest renal care services providers to build and support patient digital initiatives such as migration of patient-facing clinical applications to a hyperscaler cloud platform and their integration with electronic medical record systems. The benefit to the customer includes improved value-based care to patients across all touch points. Let me now talk about skill development and hyperscaler partnerships. We continue to invest in training our teams on AI, ML and Gen AI tools with the current tally at around 950-plus hyperscaler and advanced certifications. 16,000-plus of our developers and engineers are trained on code assist and productivity tools, such as Microsoft GitHub Copilot, Amazon Core Whisperer, Amazon Q and other modern application development tools. Keeping up the momentum on our hyperscaler partnerships, we announced a population health management solution, leveraging Microsoft Azure Open AI service. Aligned with value-based care models, the solution identifies social determinants of health to determine patients nonclinical needs and better predict the cost of care driven by clinical conditions. It helps patients receive quality care at the right time and in the right place while optimizing capacity and cost effectiveness for health care providers and organizations. Lastly, we are thrilled to announce that we have expanded our partnership with IBM by signing the IBM Services Business Partner agreement. This agreement will allow us to jointly work on deals with IBM as well as co-create end-to-end technology assets, primarily focusing on the Watson X Data and AI platform. Moving on to the awards and recognitions for the quarter from leading analyst firms. Q4 saw us get continued recognition from industry leading analyst firms and associations. To mention a few, Dr. Anand Deshpande received Ernst & Young Entrepreneur of the Year Award 2023 in the services category. Persistent has been recognized for a significant achievement in HR Excellence at the 14th CII National HR Excellence Award for the year 2023, 2024. Persistent was ranked as a leader for the second year in a row and a star performer by average group for software product engineering services. Persistent has been named a market leader in the HFS horizons, assuring the Generative Enterprise 2024 Horizon study. And finally, Persistent achieved Partner of the Year without systems for the sixth consecutive year for collaboration with clients for long-term success, delivering ROI and creating new solutions. This completes the section on key wins and awards and recognitions. With this, let me hand it back to Sandeep.
Thank you, Saurabh. In summary, we continue to deliver robust revenue growth and LD deal bookings in financial year '24 despite a difficult macro environment. We continue to work as a strategic partner with our customers, enabling them to drive their key business imperatives. As we enter financial year '25, we remain confident in our ability to continue a healthy growth trajectory. With this, we would like to conclude the prepared comments and would like to request the operator to open the floor for questions.
[Operator Instructions] The first question is from MetaPack.
Congrats for a good set of numbers. A couple of questions. Firstly, on the BFSI vertical. Good to see growth coming back after a couple of quarters. So I just want to understand what is broad-based growth? And should we expect that BFS has bottomed out and we should see good accretion from year on? Any comments over there would be helpful. Secondly, on the top client, we have seen a decline for the past 2 quarters very sharply. So just want to understand, is there further headwinds ahead? Or is this the last of the ramp-down we have seen? And what is the trajectory going forward for that client? And if a third question, I may within on the margins. We saw very strong growth this year, but still the margins can expand. And I think for next year also, you're aiming to maintain margins. So what kind of growth is required for us to see margin expansion come through?
Sure. Multiple questions there, so I'll try and address the specific. So as far as the largest customer is concerned, look, some of the ramp downs are planned ramp downs. So when we do larger deals, there are productivity things built year-on-year. And so these are not any surprises. So I would be -- if there was any surprises that would have been told very clearly. So all of this is planned ramp downs. So we have a good trajectory. We know where we are headed. So I don't think there is anything to worry about in the top customer or from that matter, it's not a pattern. Second part, when you talk about the margins growth. So look, it is not lost on us that the market is tough outside. So if you look at our peer results, growth is difficult to get in these environments. So our first job is to make sure that we grow and grow at the industry-leading growth rates. For that, we have to do investments in sales and marketing, which are at a heightened level, coupled with the GenAI kind of initiatives where we are learning, we are all deploying our manpower to build capabilities on top of the AI capabilities that we have. We have also opened customer experience centers as we announced in the last quarter across the U.S., London and in Pune and so on. So there's a lot of investment that is going in from a capability perspective and winning against the bigger peers and the mid-tiers in difficult times. So from that perspective, rest assured, as the headwinds kind of from an industry perspective subside, we have built enough muscle and the growth should take care of the margin expansion. But having said that, first focus is to make sure growth at reasonable margins is where it is. Now coming to the BFSI side. So again, one bigger thing that if you look at persistent overall, BFSI, healthcare life sciences put together an even in tech companies, we are gaining ground as a challenger to the bigger firms. More and more, we are seeing a pattern where bigger customers are not very happy with the large incumbent providers that they have. We are being invited in. We are winning against these in the larger landscape and some of the ramp-ups that you're seeing in different industry verticals are based on that. So same thing is happening in BFSI as well. We have opened some fairly large accounts, and they are on the ramp up. So that is the overall kind of commentary on the questions you had.
The next question is from Manik Taneja.
Once again, congratulations for the steady execution, Sandeep. Just wanted to get your thoughts around a couple of aspects. Number one, on the health care side, we've seen very, very strong growth through the course of the last few quarters. How should we be thinking about near-term growth in the health care side, given this is largely being led by one large deal ramp up? That's question number one. The second question was for Sunil. In terms of our revenue metrics breakup, we see that the software license element essentially as gone up in Q4 compared to Q3, which is unlike the usual seasonality. If you could help us understand what's driving that? And how should we be thinking about this aspect?
Sure. So I'll take the first question and hand over to Sunil for the second answer. So as far as the health care is concerned, so let me clarify. Yes, we have had a fairly large win in a fairly large customer, but that's not the only win that we are in. So if you look at our health care life sciences business, our team has been built over the last couple of years, and we have put the muscle. I'm pretty happy with the way the team has shaped up. And we have had multiple wins. So one large win, multiple other wins in the middle kind of deal sizes is what is ramping up. And from our perspective, and I'm sure a lot of you would be curious. The banking order for us -- for this financial year would be basically healthier life sciences, followed by BFSI and companies BFSI tech companies will kind of depending on the different quarters, be neck to neck or a little ahead of each other. So that's where it is. Sunil, over to you for the software license.
So Manik, what is happening from our inmate perspective is the deals that we have had in the recent couple of quarters have a trend where we are taking on managed services deals, we are setting up infrastructure lab, which require us to buy licenses on behalf of the clients. That is one. Second is it's maybe a little too early and that has not reflected in the numbers but there is a trend in the market that the customers on their own enterprise customers are trying to convert CapEx into OpEx, right? And when that happens, that also becomes a software license cost, which is coming in the purchase the kind of items. So not a heavy this one, but as this quarter did have these transactions that you see higher cost.
The next question is from current Karan Uppal.
So 2 questions from my side. Firstly, on M&A, because the company is sitting on a decent cash balance. So any plans for M&A in FY '25? And what verticals and service lines are you looking out? That's one. And second is on Europe. So Europe has been softer last 3 to 4 quarters. So what are the reasons for the same? And from strategic perspective also when management is targeting $2 billion revenue, how are you thinking about Europe's contribution in that?
Sure. So from an M&A perspective, look, we have a focus on M&A. We definitely are looking at different assets at different points in time. And depending on finding the right asset. And let me define our M&A strategy as well, so that you can understand where we are going. So we are looking at the customer of health care life sciences, our BFSI and Data Stash AI. That's 1 part of it. Within Healthcare Life Sciences, we are predominantly looking at things like the payer provider ecostem or the payer provider, if we may call it. That is 1 part where we are focused on similarly within BFSI. There are certain macro segments that we are focused on. In terms of geography, interestingly, we are looking at a combination of Western Europe from a business perspective, Eastern Europe from a delivery perspective. And in the last couple of years, given the conflict in that region, we have slowed down our M&A activity in that region, but we will pick it up as we go on. And even at this point in time, as I said, at any point in time, we are evaluating multiple different tuck-in acquisitions. We are not going to do acquisitions for revenue aggregation. These are capabilities, whether GenAI, AI, micro verticals and so on and so forth or delivery presence in Eastern Europe. So if we have something to announce over the next few months and quarters, we'll definitely come back. But that's definitely an area of focus, and that should also address some part of the void that we have in the European growth side.
The second part was on Europe, which has been soft for last 3 to 4 quarters. So any comments on that?
Yes. So from a Europe perspective, look, there is definitely a focus that we are bringing on to it. So if you look at our senior has, we have brought in at to lead Europe along with our BFSI vertical. So that's 1 part. And second, organically also, we have been reinforcing our team, and there will be some amount of M&A focus there as well. So over the next several quarters, we do hope to turn the corner on Europe in terms of growth.
The next question is Abhishek Bhandari.
Sandeep, I have 2 questions. The first is on your growth distribution. If you look at last 2 quarters, bulk of the growth is led by only health care vertical while we have seen some incremental improvement in PFS, it is not really very material. So if you could share some light about how you see the growth pattern across verticals in FY '25.
Sure. So you want to have the next question as well or?
Yes. The next question is on the margin profile. While we understand that your medium-term aspiration of 200 to 200 basis points remains unchanged. But now that has got -- seemed to shift it by 1 year given that we're talking about margin remaining at current levels in FY '25. Having said that, your on-site effort on these large projects may have picked out. Do you think that may give you some near-term lever to continue to invest into sales and yet give back something to the investors in terms of improvement in margin?
Sure. So I think the second question you have partly answered yourself. So if we look at it, yes, there are larger deals that we have won, which start with a certain amount of vendor consolidation at times on site, which basically, if you look at our financials and put a thread through the pattern, there are some deals which are ramping up. Contractor spend is going up, and this is also a margin lever for us as you go ahead. Look at the headcount that we have added. We've added significant headcount over the last 2 quarters, both on-site, offshore. The offshore headcount is in the hope and expectation that as we do the offshore transitions, they will get deployed and so on. So there's a pattern if you put a set to all this. Yes, there is a possibility of margin improvement. But look, as I said before, the market is tough. We don't expect it to be kind in terms of demand environment anytime soon. And as we are also growing and as we are also competing with the largest peers that we have and doing vendor consolidations, et cetera, we want to keep that decision to us in terms of improving margin in this year versus doing the right thing by growth. Improving margin is an easier task versus getting higher growth. So for this year, we're focused on growth. And at any point in time, if we can improve the margins. Rest assured, we'll do our best to improve the margins. Now in terms of the growth, while you said that HCL is the only vertical with growth, yes, we are predominantly, yes. But BFSI also, if you look at it, in an environment where most of our peer group, whoever you have seen the results from. And what we see in the market, BFSI is a tough segment as of this point in time, squeezing out growth on a quarter-on-quarter basis there means that there are more newer deals that are coming in, while we might be optimizing on the existing business as well. So rest assured, the focus is on different verticals, different service lines. And internally, the way we are structured. There are different teams going up at BFSI, different P&L leader for health care life sciences and so on and so forth. So focus is on growth across. We'll let the year pan out. But high level, health care will lead the growth even for this year because of the pipeline that we have, because of the projects we have done, followed by BFSI or betting.
Sandeep, maybe 1 last question. Historically, our portfolio has been very discretionary in nature. Maybe in the last 3, 4 years, we have made it more annuity-driven, long-term contract driven. As things stand, in your assessment, how much lift and discretion demand is critical for you to hit a 14%, 15% kind of growth. Do you think the pipeline is enough and the exit rate is enough to you to kind of go to a double-digit growth? Don't give me a number, but you maintain that you'll have an industry leading growth in '25. Some of your large peers are talking about better '25 than '24.
So we have delivered, if you look at the financial year we've delivered 14.5%. If you look at the overall industry and take an average for our peers in the industry, whether you look at the Indian space or otherwise, it will not be more than 3% to 4% at an average of all the service providers that we track. Now if you look at the last 3 years as well, even before this, so the relative outperformance of our assistant has been fairly decent. And that has been in the same environment where we have been asked this question about discretionary, nondiscretionary. So rest assured, discretionary or nondiscretionary, we are not waiting for the demand to come back, where we can deliver relative outperformance we will, and we are confident that this year should also an out relatively.
The next question is from Raveen.
So can rain and a good quarter. I wanted to ask you about the top line. You said that this is a planned ramp down and this was a large deal that you had signed in FY '23. So is there any renegotiation as well in this? Or this was just productivity improvement and other things that are baked in right when you signed the contract. What I'm trying to say is whether the client is actually changed any part of the contract or restructure it.
Sure. So this is -- there is no renegotiation. There's no contract opening. This is as per the contract we signed as per the planned revenue profile for the years. And so there is no concern on any of those kind of issues that you talked about. So this is a fairly straightforward, what was planned is what is being done.
Great. And on Sasa, are you licensing this? Or are you just using this as something to bake into your bids and improve your win rates?
Yes. So our clients have definitely asked us for the licensing model for this, but our attempt here is not to use this as a product, product, but use this as a accelerator, as an IP that we will use so that we can retain the value and capture more value in services as we go around rather than just using it as another part of our Accelerite business or earnings.
Okay. And lastly, on margins. Can we think about the margin improvement as being possible when the demand environment improved because you were saying that you have overinvested a bit deliberately in sales. So can we see that normalize when demand comes back?
Yes, absolutely. And if you look at it, we have been saying this for some time. And even if you were to follow our organization. If you look at the leaders that we have brought in, right from Ion as the Chief Strategy and Growth Officer, but as for Europe Financial Services, PV as the Chief Operating Officer, many others. So we are putting a muscle whether it is a bad economy or a good economy, we are preparing ourselves to go to $2 billion and much beyond. And so from our perspective, if the market conditions become more able and the growth becomes easier because the demand comes back, you should definitely see the leverage of all these investments coming.
The next question is from Sandeep Shah.
Congrats on a good set of numbers. Sandeep, the first question is entering FY '25 versus entering FY '24. Based on client discussions, do you foresee some change in terms of the client pattern in terms of discretionary spend award because some of your hyper peers on the hyperscalers are saying cost optimization effort on the workload migration has been bottoming out some of your other global MNCs who are into software product engineering. They are saying some of the projects which were on sold in terms of discretionary pattern have been coming back. Are you be witnessing? And if that turns out to be true, do you believe FY '25 could be better for us despite we are doing much better than the industry?
Yes. So we are not seeing any of that. We are seeing same kind of a demand environment as it was there 2 quarters, 3 quarters back. And we'll be happy to see a change in the demand environment. And so should the demand environment change, as I said earlier to Ravi as well, we'll let it pan out, but we are preparing ourselves for a status quo in terms of the demand environment and performing relatively well within that.
Okay. And can we come in to the margins. I think a search of changing the growth profile from just being project-based and a discretionary based, we even a managed services player. That may lead to many contracts where we may have to schedule a planned ramp down. We have to do slightly higher on-site efforts, slightly higher subcontracting costs. So why we call out this as a one-off cost? And this may postpone your margin achievement target of 200, 300 bps. When do you expect that movement to start happening? Will it be FY '26 or beyond that?
Look, there are multiple things that are happening. So there's not just the large bonds. If you look at it, we have been talking about how we are investing in Generative AI. How we have put labs together, how we have put customer experience centers together, we have brought in overall management bandwidth and so on. So there is multiple things there. And we are today preparing for an environment where we will increasingly fight bigger deals against the bigger peers. And this will become part of the courts, whatever the transition costs are and so on and so forth. And as I said earlier, look, all these investments are to make sure we maintain our growth trajectory while maintaining the margins at where they are. And as the demand environment makes itself amenable to more growth. I'm pretty sure with that and with time, all of these will have a better leverage and margin should improve. And we remain committed to our next 2 to 3 years, 200 to 300 basis points, and we have a line upside to that.
The next question is from Mohit Jain.
First is on the TCV toppers to me, TCB Y-o-Y is a little on the slower side. If I look at on both sides. So is there a spillover or something that you guys are expecting from 1Q? Or this is just a reflection of the current environment we are in and this is the new normal for TCV?
So if you look at the TCV, if you are comparing it with the earlier years and so on and so forth, the demand environment should be kept in mind. I don't think we are concerned about any slippage that happened in the last quarter that will come in this quarter and so on and so forth. We are relatively okay with the TCV that we delivered. It can always be better and we'll try to do better. But we are comfortable with where we landed with that and we have a decent pipeline.
And second one on margins. So you had 300 basis point margin benefit because of the earnout reversal. But in the opening remark, I think there was this 200 basis points mentioned. So what is our recurring margin or true margin for this quarter?
You want to answer that?
Yes. So Mohit, the question we hear about is how much of the earnout reversal liability we have line of sight to recruit. So on multiple levers both on the subcontractor cost reduction because of on-site offshore movement and purely the utilization improvement and some of the costs that we talked about were one time. The transition cost that we talked about and the travel costs that also happened in the last quarter. I think we have a good line of sight to have EBIT margins in a normal operations at the level of 14.5%.
The next question is from Gabor Single.
Congrats, Sandeep and team, for very strong execution yet again. Just 2 questions from my side. Sandeep, I just wanted to check on the hi-tech segment. You mentioned that ex of the top line, the high-tech segment did grow in this quarter as well. But what is the overall outlook in this segment going forward for FY '25? Again, excluding the top line. Are the clients coming back on the spend? And what is the kind of demand that we are expecting from that segment? My second question is a broader level question for Persistent as a company. Now that we are well over $1 billion of revenue in size. What are the challenges? Company-specific challenges that we see For ourselves. I mean we'll keep aside the macro part, which is, of course, same for everybody. But as a company, I mean, in terms of being able to win large managed services deal in terms of, let's say, if there is more of a pass-through revenue, which impacts our ability to expand margins. Any things of those sorts, which you believe are the things that you are probably taking at the top of your to-do list to tackle in the coming years.
So as far as the high-tech segment is concerned, you are right, ex of the large customer, it definitely grew. Now high-tech segment is obviously facing the headwinds because of the enterprise customers. The enterprise customers face challenges in their business, their downstream ability to buy from these enterprise software companies, which is what comprises high tech for us predominantly is under pressure. So we do expect that for the next few quarters, there will be pressure in this segment, and we are trying to build our pipeline in a way that we can still deliver the growth, and we'll let it pan out. Now coming to the company's specific challenges, which is really interesting. So I would say it is not about challenges. It is about, as we scale, as we are invited more and more to the party in terms of being a challenger, where there's a fatigue with the larger peers of ours, where people see a refreshing change in the technology capabilities that we have from bringing the product engineering tenants into the enterprise market or otherwise, capabilities around generative AI, AI, other emerging technologies where they really see the differentiation and they see the refreshing change in our agility in terms of our response. It's not just about what we do, how we do, the customer experience that we provide. It is definitely opening more doors for us. Now for us, obviously, the challenge is to bring in the newer set of thinking, whether it is in terms of how do we mine our existing customers to become bigger and more relevant or we open newer accounts at scale where we have been invited. So if you look at our management hires over the last 1 year, even in the last 2 years, you will find that is where we have been incrementally building the muscle. So I do think it's a very healthy challenge in Europe, and it's a very, very good opportunity for us. And that's where if you look at it, this is the 16th state quarter of revenue increase. And if you look at it, if you do a relative outperformance with the sector, as I said, last year, the sector grew by about 3% to 4%, we grew at 14.5%. And in the last 2 years before that, we do at 35% each year. So I do think there's a great market opportunity for us and for us to grab it, bring the right skills, muscle, and that's what we are focused on. It's all about execution now. Hopefully, that answers it for you.
The next question is from Karan Gampi.
So 2 questions from me. It's interesting that your life sciences vertical is the healthiest because when we speak to enterprises, it's the life sciences vertical that AI is mission-critical. I think 9 of the 10 top life sciences companies want to build Les by year-end. So perhaps you can address the TAM, the competitive position? And how many more of these big deals can we win? Because it does seem like a vertical that's quite right for businesses like yours to come in and handhold them through that process? That's the first question. The second question would be, it is quite evident if you speak to those close to the cloud business that there has been an acceleration of consumption within the cloud. And the degree of acceleration can be debated but no doubt there is acceleration. So how do we reconcile in AWS that could potentially reaccelerate to maybe 25% growth by year-end. And the relative, I would say, just very neutral, I would say, commentary from us on the lack of visibility ahead because it sort of -- it doesn't quite reconcile. Essentially, there can't be that much of a delta in the conversion rates from ERCs to production or Amazon versus you. So I would just be curious as to why there's this dark delta? Is it just because a lot of their revenues are driven by clusters, which you do not monetize as the GPU clusters, which we don't monetize and it takes a few quarters? And so it's the sequencing argument? Or you are missing something else would be good to understand.
Sure. So Kharan and I will be respectful of time. We had 3 minutes before the call has to finish. So I try and answer your first question. Second, I think we can take it off-line because it's a fairly long debate there. So if you look at the life sciences, health care vertical overall, the health vertical for us is broken into pharma/biopharma, sending against teens medical devices, payer and providers. If you look at the use cases in terms of AI, we are involved in each one of these segments, whether it is in the research side with a pharma set of companies, whether it is with even providers like radiology, where we are working with some of the leading firms in that where we are working on building AI/ML solutions for them to further enhance the quality of output that our radiologists, for example, can bring to the market. And even reduce the cost of the entire value chain, right from patient recruitment to the end result being delivered and giving them increased revenue on one hand, decrease the cost of. Similarly, in payer providers, there are multiple use cases that we are working on using AI/ML and GenAI as well. And we are talking about a few of these in our earnings call today and as well as the other things are concerned, if the -- all the more part to all the hyperscalers, if their revenues increase, I'm pretty sure our revenues will follow as well. So we'll closely watch that, and we'll take it offline in terms of the bigger discussion on consumption, GPUs versus others and so on. Since we have only 2 minutes, I want to make sure we take one more question before we close to that.
The next question is from Nitin Padmanabhan.
Three questions. So one is a couple of players. I think the early results have been talking about rescoping of existing contracts that coming up in between. So what's your thought on that within your portfolio? The second thing is on BFSI. If you could just contrast BFSI in your portfolio versus what it was maybe a year ago? How have things changed in terms of dynamics? You mentioned that it continues to be a tough area. But I think people have also been talking about a bottoming out there. So just your thoughts there with reference to your portfolio. And finally, on managed services, how is managed services sort of being on the portfolio, maybe, let's say, 3 years ago versus now as a percentage of revenue? Is it meaningful today versus what it was? So there are 3 questions.
Nitin, we are nearly out of time, so I'll quickly go short burst over all this. As far as the rescoping of contracts is concerned, I don't think we have seen any major rescoping of contracts. There may be minor things which are part of the cost. There is definitely at times, very large customers may come in, basically, when your quota is due not give a quota or try to not give the core and so on and so forth. We are seeing more of that rather than reporting in Ares. BFSI large customer dynamics. So we have been gainer of the phenomena where, as I said before, customers are not very happy with larger increments. They are looking towards challengers to come in and bring in the right technology capabilities and the agility that they need. That's where we have opened some fairly large logos, and we are seeing some ramp up there that should only accelerate with that. Managed services, definitely, if we were to look at it, simple things like what we are talking about, if you listen to our earnings calls in the past as well. Private equity, for example, we have become a private equity carve-out specialist. So if private equity goes in as audit NewCo from a large company need kind of a new greenfield IT and then there's a managed services for the next 3 to 5 years. That's where we have won significant deals in the last 3 years. And so there's a good proportion of managed services coming from things like that to our newer customers, existing customers and so on. So hopefully, that gives you a color. We are out of time. So I would want to, with this take a pause here. So with this, we would like to close the call with a message that we are positive on our great prospects as we move into FY '25. We would once again like to thank our 23,800-plus team members, customers, partners, investors and all of you for their support in our growth journey. Thank you for spending time with us on the call today. We look forward to connecting with you again in 3 months' time to provide an update on our progress. Thank you.
Thank you very much to the persistent management. Ladies and gentlemen, on behalf of Persistent Systems Limited, that concludes today's conference. Thank you for joining us, and you may now disconnect your line and executive in. Thank you.